



TOPOTARGET
Answers for cancer

To NASDAQ OMX Copenhagen A/S
Announcement No. 12-09 / Copenhagen, 20 April 2009

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

Positive sales growth for Savene[®] and Totect[®] in Q1 2009

Copenhagen, Denmark – 20 April 2009 – TopoTarget A/S (OMX: TOPO) announces continued increased growth of 66% from DKK 7.0 million to DKK 11.6 million in sales of Savene[®] and Totect[®] in Europe and the US in Q1 2008 compared with Q1 2009.

Sales of TopoTarget's first marketed product, Savene[®] and Totect[®], continue to rise. In 2008, we were close to doubling our sales from DKK 21.9 million to DKK 39.1 million relative to 2007.

Sales have continued to climb from DKK 3.7 million in Q1 2007 to DKK 7.0 million in Q1 2008 and now to DKK 11.6 million in Q1 2009. This is an increase from Q1 2007 to Q1 2008 of 89%, from Q1 2008 to Q1 2009 of 66%. Since Q3 2008 sales of Savene[®] and Totect[®] have generated a profit for the product in the two continents.


The sales figures show that more and more European and US doctors and nurses are using the product.

TopoTarget estimates that the combined market in the US and Europe for Savene[®]/Totect[®] represents DKK 40-50 Euro per year.

Savene[®]/Totect[®] is the only approved and evidence-based treatment of anthracycline extravasation and has been recommended by oncology nurse organisations on both sides of the Atlantic, a key factor for the product's dissemination.

"It is highly satisfactory that sales of Savene[®]/Totect[®] continue to increase and that we now have a net profit on the products and I'm very happy to see that our products create value for cancer patients," says professor Peter Buhl Jensen, CEO of TopoTarget.

TopoTarget announces positive sales growth for Savene® and Totect® in Q1 2009



TopoTarget A/S

For further information, please contact:

Peter Buhl Jensen
CEO

Telephone +45 39 17 94 99
Mobile +45 21 60 89 22

Background information

About Savene®/Totect®

Savene®/Totect® is a catalytic inhibitor of Topoisomerase II, an enzyme found in the cell nucleus. Topoisomerase enzymes are essential for cell growth and proliferation and the target for a group of anti-cancer chemotherapeutics called anthracyclines. Savene®/Totect® blocks the activity of the topoisomerase enzyme and prevents the effect of anthracyclines.

Savene®/Totect® is used as a detoxifying agent, administered intravenously as an antidote following an extravasation. An extravasation is a serious clinical accident in which anthracyclines accidentally leak into surrounding tissue. The high concentration of drug causes severe and cumulative damage to the skin, subcutaneous tissue, muscle and nerves. Current treatment often involves surgical removal of the tissue followed by plastic surgery and rehabilitation. The use of dexrazoxane (the active ingredient in Savene®/Totect®) to treat anthracycline extravasation is protected by patent in several countries including EU and the US. The US patent number is 6,727,253 B2.

About TopoTarget

TopoTarget (OMX: TOPO) is an international biotech company headquartered in Denmark, dedicated to finding "Answers for Cancer" and developing improved cancer therapies. The company was founded and is run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer.

TopoTarget announces positive sales growth for Savene[®] and Totect[®] in Q1 2009



TopoTarget has a broad clinical pipeline but is currently focusing on the development of belinostat, which has shown proof of concept as monotherapy in treating haematological malignancies and positive results in solid tumours where it can be used in combination with full doses of chemotherapy, and is in phase III in PTCL. TopoTarget's expertise in translational research is utilizing its highly predictive in vivo and in vitro cancer models. TopoTarget is directing its efforts on key cancer targets including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors. The company's first marketed product Savene[®]/Totect[®] was approved by EMEA in 2006 and the FDA in 2007 and is marketed by TopoTarget's own sales force in Europe and the US. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.